Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : University of Colorado School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
RS BioTherapeutics Announces Research Collaboration with University of Colorado
Details : The collaboration aims to advance the clinical development of RSBT-001, which is being evaluated in the early-stage clinical trial studies for the treatment of COPD and IPF.
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 08, 2024
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : University of Colorado School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Cannabidiolic Acid Complex
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, an investigational semi-synthetic cannabidiolic acid complex, in a preclinical pulmonary fibrosis model.
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 29, 2023
Lead Product(s) : Cannabidiolic Acid Complex
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : National Institute on Alcohol Abuse and Alcoholism
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Recipharm AB
Deal Size : Undisclosed
Deal Type : Partnership
RS BioTherapeutics Selects Recipharm as Product Characterization Partner
Details : Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD).
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Recipharm AB
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabidiolic Acid Complex
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Synthonics
Deal Size : $3.0 million
Deal Type : Financing
RS BioTherapeutics Secures $3 Million Seed II Round of Funding
Details : RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 26, 2022
Lead Product(s) : Cannabidiolic Acid Complex
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Synthonics
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Synthonics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2022
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Synthonics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Synthonics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound
Details : Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (C...
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 23, 2022
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Synthonics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?